Some key points emerging from the COX-2 controversy

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 3, 2005, Pages 145-147

  Urquhart, John ^a,b,c,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UCSF ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AARDEX Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NEW DRUG; ROFECOXIB;

BUDGET; CARDIOVASCULAR RISK; DECISION MAKING; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EXPOSURE; DRUG INFORMATION; DRUG INHIBITION; DRUG LEGISLATION; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GOVERNMENT REGULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; UNITED STATES;

CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LACTONES; NEWSPAPERS; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 14944366330     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1076     Document Type: Editorial

References (12)

1. Harris G. At FDA, strong drug ties and less monitoring. NY Times, December 6, 2004.
2. Rubenstein S. Q&A: How best to monitor drugs after they're FDA-approved. Wall St J, December 20, 2004.
3. Harris G. A 4th Painkiller is tied to increased heart risk. NY Times, December 21, 2004.
4. Mathews AW. Second opinion: as drug-safety worries grow, looking overseas for solutions. Wall St J, December 31, 2004.
5. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
6. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004; 364: 1995-1996.
7. Boers M. Letter. Lancet 2004; 364: 25-26.
8. Yussuf S, Hawken S, Öunpuu X, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
9. Hanley JA, Lippman-Hand A. If nothing goes wrong is everything all right? interpreting zero numerators. JAMA 1983; 249: 1743-1745.
10. Urquhart J. How long do pharmaceuticals stay in the market-place? J R Stat Soc Ser A 2003; 166: 274-277.
11. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-291.
12. British Medical Association. Living With Risk: The British Medical Association Guide. John Wiley & Sons: Chichester, UK, 1987.